AU6620698A - Bicyclic aromatic amino acids - Google Patents

Bicyclic aromatic amino acids

Info

Publication number
AU6620698A
AU6620698A AU66206/98A AU6620698A AU6620698A AU 6620698 A AU6620698 A AU 6620698A AU 66206/98 A AU66206/98 A AU 66206/98A AU 6620698 A AU6620698 A AU 6620698A AU 6620698 A AU6620698 A AU 6620698A
Authority
AU
Australia
Prior art keywords
amino acids
aromatic amino
bicyclic aromatic
bicyclic
acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU66206/98A
Other versions
AU735313B2 (en
Inventor
Beate Diefenbach
Simon Goodman
Joachim Marz
Peter Raddatz
Friedrich Rippmann
Matthias Wiesner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU6620698A publication Critical patent/AU6620698A/en
Application granted granted Critical
Publication of AU735313B2 publication Critical patent/AU735313B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/361,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/101,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/141,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/161,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/201,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU66206/98A 1997-02-13 1998-02-06 Bicyclic aromatic amino acids Ceased AU735313B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19705450A DE19705450A1 (en) 1997-02-13 1997-02-13 Bicyclic aromatic amino acids
DE19705450 1997-02-13
PCT/EP1998/000636 WO1998035949A1 (en) 1997-02-13 1998-02-06 Bicyclic amino acids

Publications (2)

Publication Number Publication Date
AU6620698A true AU6620698A (en) 1998-09-08
AU735313B2 AU735313B2 (en) 2001-07-05

Family

ID=7820093

Family Applications (1)

Application Number Title Priority Date Filing Date
AU66206/98A Ceased AU735313B2 (en) 1997-02-13 1998-02-06 Bicyclic aromatic amino acids

Country Status (25)

Country Link
EP (1) EP0964856B1 (en)
JP (1) JP4327257B2 (en)
KR (1) KR20000071030A (en)
CN (1) CN1085205C (en)
AR (1) AR010894A1 (en)
AT (1) ATE225776T1 (en)
AU (1) AU735313B2 (en)
BR (1) BR9807345A (en)
CA (1) CA2280727C (en)
CY (1) CY2341B1 (en)
CZ (1) CZ297366B6 (en)
DE (2) DE19705450A1 (en)
DK (1) DK0964856T3 (en)
ES (1) ES2183332T3 (en)
HU (1) HUP0001138A3 (en)
ID (1) ID22533A (en)
NO (1) NO313289B1 (en)
PL (1) PL335101A1 (en)
PT (1) PT964856E (en)
RU (1) RU2187506C2 (en)
SI (1) SI0964856T1 (en)
SK (1) SK284646B6 (en)
TR (1) TR199901962T2 (en)
WO (1) WO1998035949A1 (en)
ZA (1) ZA981178B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063790A1 (en) * 1996-05-31 2004-04-01 The Scripps Research Institute Methods for inhibition of angiogenesis
CN1140511C (en) 1998-04-09 2004-03-03 明治制果株式会社 Amino piperidine derivatives as integrin alpha beta 3 antagonists
BR0009739A (en) 1999-04-13 2002-04-09 Basf Ag Compound, medicine, pharmaceutical preparation, and, uses of a structural element, a compound and a pharmaceutical preparation
WO2001010844A1 (en) 1999-08-05 2001-02-15 Meiji Seika Kaisha, Ltd. φ-AMINO-α-HYDROXYCARBOXYLIC ACID DERIVATIVES HAVING INTEGRIN αvβ3 ANTAGONISM
JP2003519119A (en) * 1999-12-24 2003-06-17 スミスクライン ビーチャム パブリック リミテッド カンパニー (Hetero) bicyclylmethanesulfonylamino-substituted hydroxamic acid derivatives
WO2001055104A1 (en) * 2000-01-25 2001-08-02 Kaneka Corporation Process for preparation of optically active n-substituted azetidine-2-carboxylic acids
KR20030061390A (en) * 2000-11-01 2003-07-18 메르크 파텐트 게엠베하 Methods and compositions for the treatment of diseases of the eye
US7514098B2 (en) 2001-05-30 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Use of targeted cross-linked nanoparticles for in vivo gene delivery
MXPA04000839A (en) 2001-08-01 2004-05-14 Merck Patent Gesellscahft Mit Integrin inhibitors for the treatment of eye diseases.
CN1658894A (en) * 2002-02-14 2005-08-24 默克专利股份有限公司 Methods and compositions for the treatment of eye diseases
DE10305784A1 (en) * 2003-02-12 2004-08-26 Merck Patent Gmbh 3-Oxo-3,4-dihydro-2H-benz-(1,4)-oxazin-6-yl)-propionic acid derivative preparation, for use as integrin inhibitors with e.g. antitumor action, by multi-stage process giving diastereomerically pure product
DE10337863A1 (en) 2003-08-18 2005-03-17 Merck Patent Gmbh Use of chromene-4-one derivatives
EP1765362B1 (en) * 2004-06-04 2012-03-28 The Scripps Research Institute Compositions and methods for treatment of neovascular diseases
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
RU2518073C2 (en) * 2008-12-26 2014-06-10 ДАЙНИППОН СУМИТОМО ФАРМА Ко., ЛТД. Novel bicyclic heterocyclic compound
WO2011024987A1 (en) * 2009-08-31 2011-03-03 塩野義製薬株式会社 Aromatic fused heterocyclic derivative and pharmaceutical composition containing same
TW201350475A (en) 2012-03-06 2013-12-16 Boehringer Ingelheim Int Benzodioxane inhibitors of leukotriene production for combination therapy
JP6256467B2 (en) 2012-07-17 2018-01-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pyrazole derivatives that inhibit leukotriene formation
JP2016523982A (en) 2013-07-15 2016-08-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Inhibitors of leukotriene production
EP3022193B1 (en) 2013-07-15 2017-04-26 Boehringer Ingelheim International GmbH Inhibitors of leukotriene production
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
CA3221177A1 (en) 2021-11-01 2023-05-04 Meghan Kerrisk Campbell Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU675689B2 (en) * 1992-12-01 1997-02-13 Merck & Co., Inc. Fibrinogen receptor antagonists
EP0760658B1 (en) * 1994-05-27 2002-11-13 Merck & Co. Inc. Compounds for inhibiting osteoclast-mediated bone resorption
DE19548709A1 (en) * 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosine derivatives
DE19654483A1 (en) * 1996-06-28 1998-01-02 Merck Patent Gmbh Phenylalanine derivatives
KR20000022190A (en) * 1996-06-28 2000-04-25 플레믹 크리스티안 Phenylalamine derivatives as integrin inhibitors

Also Published As

Publication number Publication date
PT964856E (en) 2003-02-28
JP2001511789A (en) 2001-08-14
CN1085205C (en) 2002-05-22
DE59805895D1 (en) 2002-11-14
TR199901962T2 (en) 1999-12-21
KR20000071030A (en) 2000-11-25
EP0964856A1 (en) 1999-12-22
AU735313B2 (en) 2001-07-05
DE19705450A1 (en) 1998-08-20
PL335101A1 (en) 2000-04-10
SI0964856T1 (en) 2003-04-30
AR010894A1 (en) 2000-07-12
CN1252064A (en) 2000-05-03
EP0964856B1 (en) 2002-10-09
CZ297366B6 (en) 2006-11-15
CZ287599A3 (en) 1999-11-17
ATE225776T1 (en) 2002-10-15
SK284646B6 (en) 2005-08-04
ES2183332T3 (en) 2003-03-16
SK107199A3 (en) 2000-05-16
CY2341B1 (en) 2004-02-06
NO993901L (en) 1999-10-12
CA2280727A1 (en) 1998-08-20
ZA981178B (en) 1999-05-21
CA2280727C (en) 2008-05-06
NO313289B1 (en) 2002-09-09
WO1998035949A1 (en) 1998-08-20
DK0964856T3 (en) 2003-02-10
JP4327257B2 (en) 2009-09-09
HUP0001138A2 (en) 2001-05-28
NO993901D0 (en) 1999-08-12
BR9807345A (en) 2000-03-21
HUP0001138A3 (en) 2002-10-28
RU2187506C2 (en) 2002-08-20
ID22533A (en) 1999-10-28

Similar Documents

Publication Publication Date Title
AU6620698A (en) Bicyclic aromatic amino acids
AU6482398A (en) Sulfonylaminocarboxylic acids
AU4922497A (en) Interleukin-18-receptor proteins
AU6721696A (en) Cd44-like protein
AU2972097A (en) Peptide derivatives
AU5477898A (en) Phytase combinations
AU2091799A (en) Uses of alpha-conotoxin peptides
AU1803597A (en) Peptide derivatives
AU6593898A (en) Substituted 6- and 7-aminotetrahydroisoquinolinecarboxylic acids
AU5031598A (en) Immune-modulation with amino acids
AU6881998A (en) Single-chain double-alpha peptide
AU5061698A (en) Peptide derivatives
AU1999999A (en) Contryphan peptides
AU1684099A (en) Amino acid derivatives
AU6000698A (en) Proteins
AUPO957397A0 (en) Transporter protein
AU8176798A (en) Secreted proteins
AU6275098A (en) Novel h-rev 107-like protein
AU6421298A (en) Novel synthetic polypeptide
AU4582597A (en) Therapeutic proteins
AU6692198A (en) Novel proline-rich acidic protein
AU9318798A (en) Ras-like protein
AUPO324096A0 (en) Linker peptide
AUPO507197A0 (en) Peptide polymers
AU9592298A (en) Secreted protein zsig-11

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)